Suchergebnisse - "Oh, Iekuni"

PubPharm (152)

1

Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults

enthalten in: Leukemia research | 2024

von Oh, I. | Hatano, K. | Ikeda, T. | +19

2

NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia

enthalten in: International journal of hematology | 2022

von Marumo, A. | Wakita, S. | Morita, K. | +38

3

Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose

enthalten in: Internal medicine (Tokyo, Japan) | 2022

von Kubota, K. | Imai, Y. | Oh, I. | +3

4

Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation

enthalten in: Leukemia & lymphoma | 2022

von Nagayama, T. | Fujiwara, S. | Kikuchi, T. | +21

5

Efficacy and safety of blinatumomab : Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

enthalten in: Asia-Pacific journal of clinical oncology | 2022

von Kobayashi, Y. | Oh, I. | Miyamoto, T. | +11

6

NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia

enthalten in: International journal of hematology | 2022

von Marumo, A. | Wakita, S. | Morita, K. | +38

7

NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia

enthalten in: International journal of hematology | 2022

von Marumo, A. | Wakita, S. | Morita, K. | +38

8

NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia

enthalten in: International journal of hematology | 2022

von Marumo, A. | Wakita, S. | Morita, K. | +38

9

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia

enthalten in: Blood advances | 2022

von Wakita, S. | Sakaguchi, M. | Oh, I. | +50

10

Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia : Final Results from an Expansion Cohort

enthalten in: Acta haematologica | 2022

von Goto, H. | Ogawa, C. | Iida, H. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[16]